Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) COMBINED CONDITIONING REGIMEN FOR ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT) IN STANDARD-RISK MYELOID-LEUKEMIA
Autore:
TAKAHASHI S; OSHIMA Y; OKAMOTO S; NISHIWAKI K; NAGAYAMA H; INOUE T; TOJO A; TANI K; ASANO S;
Indirizzi:
TAKAGI HOSP,DEPT HEMATOL,141-11 SAKEMI FUKUOKA 831 JAPAN UNIV TOKYO,INST MED SCI,DEPT HEMATOL ONCOL TOKYO JAPAN UNIV TOKYO,INST MED SCI,DEPT BLOOD TRANSFUS TOKYO JAPAN
Titolo Testata:
American journal of hematology
fascicolo: 4, volume: 57, anno: 1998,
pagine: 303 - 308
SICI:
0361-8609(1998)57:4<303:RHGF(C>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Keywords:
GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF); ALLOGENEIC BONE MARROW TRANSPLANTATION (BMT); ACUTE MYELOCYTIC LEUKEMIA (AML); CHRONIC MYELOGENOUS LEUKEMIA (CML); CYTOSINE ARABINOSIDE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
8
Recensione:
Indirizzi per estratti:
Citazione:
S. Takahashi et al., "RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) COMBINED CONDITIONING REGIMEN FOR ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT) IN STANDARD-RISK MYELOID-LEUKEMIA", American journal of hematology, 57(4), 1998, pp. 303-308

Abstract

We previously suggested that using a combined conditioning regimen including rhG-CSF with allogeneic BMT in refractory AML and CML in blastcrisis might reduce the rate of relapse and improve disease-free survival, without any major side effects, In this study, we used the same protocol for 10 AML patients in complete remission (CR) and 6 CML patients in the chronic phase (CP), We compared disease-free survival as well as toxic side effects of the regimen with 6 AML patients in CR and6 CIVIL patients in CP treated with chemoradiotherapy without G-CSF. The conditioning regimen consisted of TBI and high-dose AraC, RhG-CSF was infused continuously at a dose of 5 mu g/kg/day, starting 24 hr before the initial dose of total body irradiation (TBI) until the end ofAraC therapy, In all 28 cases, there were no early stage deaths due to regimen-related toxicity (557), None of the 10 AML cases treated with the G-CSF combined regime relapsed, In 6 AML cases treated conventionally without G-CSF, one patient died of infection and another relapsed, There were no relapses in either CML group, In the combined G-CSF group, one patient died of interstitial pneumonitis 48 days after BMT, while the rest of the CML cases are still alive. There were no relapses with rhG-CSF and no serious adverse effects in terms of RRT, acute graft vs. host disease (GVHD), or leukocyte recovery. (C) 1998 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/03/20 alle ore 14:10:01